Prevention of Thromboembolic Events
Conditions
Keywords
Renal impairment, Hemodialysis
Brief summary
BAY2433334 is under clinical development for prevention of complications in diseases such as heart attack, irregular heart beat or stroke which can arise by formation of blood clots elsewhere in the body and travels through the blood stream to plug another vessel. Renal impairment which co-occurs in elderly and patients with heart attack, irregular heart beat or stroke is a common condition in which the kidneys are not filtering the blood as well as they should. The goal of the study is to learn more about the safety of BAY2433334, how it is tolerated and the way the body absorbs, distributes and gets rid of the study dug given as a single oral dose of 25 mg tablet in participants with renal impairment and healthy participants matched for age-, gender-, and weight.
Interventions
DRUGBAY2433334 single dose in treatment groups 1-4 and 6 as well as on the dialysis free day of treatment 5
Tablet, oral
OTHERBAY2433334 on dialysis treatment day
Tablet, oral
Sponsors
Bayer
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* All participants: ≥18 years, male or female (non-WOCBP only), BMI 18-35 kg/m² (inclusive); no increased risk of bleeding or common causes of bleeding, no liver dysfunction; no CYP3A4 inhibitors/inducers; * Participants with reduced kidney function including those on kidney replacement therapy (dialysis): stable disease stratified by renal function (mild, moderate, severe, ESRD), no recent cardiovascular events; * Age-, gender- and weight-matched participants: normal kidney function, stable and well controlled hypertension and dyslipidemia acceptable, no medications influencing the coagulation system.
Exclusion criteria
Subjects with renal impairment * Acute renal failure or active nephritis. * Known impaired hepatic function. * History of definite myocardial infarction or cerebrovascular accident within the six months prior to the screening visit. * History of vascular surgery or intervention (e.g., coronary artery bypass, percutaneous transluminal angioplasty etc.) less than 6 months prior to dosing. * Congestive heart failure of New York Heart Association grade III or IV, severe arrhythmia requiring antiarrhythmic treatment. * Any other disease or condition which could influence the physiological metabolic turnover (e.g., endocrine diseases, severe infections). Age-, gender, weight matched subjects \- History of relevant diseases of vital organs or systems (e.g., of the central nervous system or other systems or organs) with the exception of mild, well controlled hypertension, dyslipoproteinemia and thyroid disorders.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cmax | Pre-dose until 96 hours after dosing | maximum observed drug concentration in measured matrix after single dose administration |
| AUC | Pre-dose until 96 hours after dosing | area under the concentration vs. time curve from zero to infinity after single (first) dose AUC(0-tlast) and AUC(0-tlast)u will be used as primary variables if mean AUC(tlast-∞) \>20% of AUC |
| Cmax,u | Pre-dose until 96 hours after dosing | maximum unbound drug concentration in plasma after single dose administration |
| AUCu | Pre-dose until 96 hours after dosing | area under the unbound plasma concentration vs time curve from zero to infinity after single (first) dose AUC(0-tlast) and AUC(0-tlast)u will be used as primary variables if mean AUC(tlast-∞) \>20% of AUC |
Secondary
| Measure | Time frame |
|---|---|
| Number of participants with treatment emergent adverse events (TEAEs) | Up to 3 days after last study medication |
Countries
Germany
Outcome results
None listed